exposing Parkinson's disease's voices and faces.

Published Date: 26 Apr 2023

One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.

Read Full News

Latest News

Self-Administered Med Shows Promise in Myasthenia Gravis

Weekly subcutaneous gefurulimab delivered early is linked to lasting symptom improvement in patients with generalized myasthenia gravis in phase 3 PREVAIL trial.

Novel PD Drug May Delay Levodopa Initiation

Tavapadon may delay levodopa use in early Parkinson’s and help stabilize dosing in the later stages of the disease, with most patients avoiding initiation or dose increases.

Tau Blood Test Detects AD Risk Years Before Brain Changes

Plasma pTau217 may detect initial buildup of AD-related brain changes before they can be detected by current ‘gold standard’ tests, such as PET scans, new research shows.

Novel Kv7 Channel Opener Reduces Seizures Without Titration

In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset and a favorable safety profile.

US FDA's Accelerated Approval for Drugs Needs More Transparency, Says Research Firm

The U.S. Food and Drug Administration should be more transparent when granting accelerated approval for certain drugs, influential drug pricing body, Institute for Clinical...

Common Genetic Cause of Intellectual Disability Identified

A newly identified recessive neurodevelopmental disorder may be among the most common genetic causes of intellectual disability and epilepsy, new research suggests.

Todays Updates

AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal

Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Upadacitinib After TNF Inhibitor Failure Improves RA Control

In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.

AAN 2026: Key RRMS Clinical Trial Updates

Dr Chu-Yueh Guo discusses promising MS trial results, including a study of fenebrutinib and positive safety data for ocrelizumab in pregnancy and pediatric patients.

Are Smartwatches Changing Arrhythmia Care?

Wearables can flag AF and capture symptoms in real time — but who truly benefits? Cardiologist Walid Amara, MD, outlines where smartwatches fit in clinical practice.

Why the FDA Rejected RP-1 in Melanoma: A Data Deep Dive

Dr Bishal Gyawali unpacks the FDA’s decision to deny RP-1 in melanoma, exploring why single-arm data and confounded response rates failed to meet the bar for clinical evidence.

Differential Diagnosis of Suspected Pulmonary Fibrosis and Efficacy of Approved Therapies

Experts review the differential diagnosis of suspected IPF, highlighting how a multidisciplinary approach confirmed the diagnosis and informed selection of optimal antifibrotic therapy.

‘Living’ Database Tracks Psilocybin Trials for Depression

Sypres.io continuously tracks and evaluates psychedelic research, offering an up-to date view of study findings, design, and limitations.

Todays Updates

AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal

Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Upadacitinib After TNF Inhibitor Failure Improves RA Control

In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.

AAN 2026: Key RRMS Clinical Trial Updates

Dr Chu-Yueh Guo discusses promising MS trial results, including a study of fenebrutinib and positive safety data for ocrelizumab in pregnancy and pediatric patients.

Are Smartwatches Changing Arrhythmia Care?

Wearables can flag AF and capture symptoms in real time — but who truly benefits? Cardiologist Walid Amara, MD, outlines where smartwatches fit in clinical practice.

Why the FDA Rejected RP-1 in Melanoma: A Data Deep Dive

Dr Bishal Gyawali unpacks the FDA’s decision to deny RP-1 in melanoma, exploring why single-arm data and confounded response rates failed to meet the bar for clinical evidence.

Differential Diagnosis of Suspected Pulmonary Fibrosis and Efficacy of Approved Therapies

Experts review the differential diagnosis of suspected IPF, highlighting how a multidisciplinary approach confirmed the diagnosis and informed selection of optimal antifibrotic therapy.

‘Living’ Database Tracks Psilocybin Trials for Depression

Sypres.io continuously tracks and evaluates psychedelic research, offering an up-to date view of study findings, design, and limitations.

Latest News

Weekly subcutaneous gefurulimab delivered early is linked to lasting symptom improvement in patients with generalized myasthenia gravis in phase 3 PREVAIL trial.

Tavapadon may delay levodopa use in early Parkinson’s and help stabilize dosing in the later stages of the disease, with most patients avoiding initiation or dose increases.

Plasma pTau217 may detect initial buildup of AD-related brain changes before they can be detected by current ‘gold standard’ tests, such as PET scans, new research shows.

In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset and a favorable safety profile.

The U.S. Food and Drug Administration should be more transparent when granting accelerated approval for certain drugs, influential drug pricing body, Institute for Clinical...

A newly identified recessive neurodevelopmental disorder may be among the most common genetic causes of intellectual disability and epilepsy, new research suggests.

News All Time

Anxiety and Depression May Raise Risk for Aneurysm Rupture

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

China Approves Market Launch Of Brain-computer Interface Medical Device in World First

China's drug regulator said on Friday that it has given the nod for a brain-computer interface (BCI) system ⁠that helps restore hand-movement ability to be sold, the world's...

Why Aren’t Canadians Getting Enough Sleep?

The change to daylight saving time and the marking of World Sleep Day call attention to the factors that contribute to sleep deficits among Canadians.

Single IV Ketamine Promising for Depression in MCI

Ketamine is well-tolerated in older adults with both mild cognitive impairment and depression and associated with improved depression scores, a new study shows.

Late Complications Common After CVT, Even After Recovery

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Activity Trackers May Predict MS Progression

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

WHO Warns Of Health Risks From 'Black Rain' in Iran

The World Health Organization warned on Tuesday that the 'black rain' and toxic compounds in the air in Iran after strikes on ⁠oil facilities could cause respiratory problems.

Wildfire Smoke Tied to Higher Stroke Risk, Greater Severity

Short-term surges in air pollution from wildfire smoke have been linked to a greater incidence and severity of stroke.

Therapeutic Research in Alzheimer’s Disease: What Is New?

Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.

Reframing Dyslexia: Ancient Genes, Modern Skill

Study argues to move beyond ‘reading genes’ — focus on conserved neural-development networks in humans to improve early screening and identify therapeutic leads.

Adults With IDDs Face ‘Mental Health Crisis’

Adults with IDDs face disproportionately higher rates of anxiety and depression and barriers to care, prompting researchers to characterize the situation as a ‘mental health crisis.’

Smoking + Parkinson's: Lower Disease Risk, Higher Mortality

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

Positive Topline Results for Efgartigimod in Ocular MG

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Does Caring for Grandchildren Slow Cognitive Decline?

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

Teen Cannabis Use Tied to Increase in Serious Mental Illness

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Recommended News For You

In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.

Chemo causes lasting physical decline in breast cancer survivors

Breast awareness: What to look for in your self-exam

Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

Adipocytes in the bone marrow offer early indicators of the development of multiple myeloma from MGUS.

The acceptance of innovative hormonal therapy for advanced prostate cancer is racialized.

Recommended Articles For You

Understanding Iron Saturation Levels in Your Blood  

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology 

Apheresis vs. IVMP in Cancer Treatment: A Tale of Two Titans 

Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

2.

According to research, hospitals can save money and help cancer patients by implementing a basic intervention.

3.

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

4.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

5.

Three out of ten breast cancers detected between screenings, study finds

1.

Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care

2.

The Lowdown on Darbepoetin: Understanding Its Uses and Side Effects 

3.

Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma

4.

The Statistical Evolution of Cancer Staging and Its Precision Impact on Prognosis and Therapy in Cancer Staging 2025

5.

Targeting Oncology: Expanding Combinatorial Strategies by 2025

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

3.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot